Publications database | www.emcdda.europa.eu

Displaying 1 - 20 of 80

m-Health applications for responding to drug use and associated harms

This paper presents results from a scoping study on the availability of smartphone-based applications in the drugs field within a European and global context. It explores the range of m-health applications available to users and professionals seeking information, support and advice in a wide range...

Rapid communication

Recent changes in Europe’s cocaine market: results from an EMCDDA trendspotter study

Using trendspotter methodology, this report explores signs of increasing availability and consumption of cocaine in Europe, in an effort to increase our understanding of recent changes in the cocaine market. The study investigates the consequences of these developments on acute health harms linked...

publication cover

Trendspotter manual: a handbook for the rapid assessment of emerging drug-related trends

This publication is a user-friendly guide, taking the reader, step by step, through the trendspotter methodology developed by the EMCDDA to explore emerging drug trends, new patterns of use, developing drug markets and technologies. The trendspotter method involves the rapid collection and...

brochure screenshot

Medical use of cannabis — brochure

One page flyer promoting the publication Medical use of cannabis and cannabinoids: questions and answers for policymaking, published in December 2018.

Joint publications

Improved drug supply indicators for Europe: progress report

This report provides a summary of the key findings from the assessment of progress of the EU Member States, Norway and Turkey towards the implementation of the revised drug supply indicators, as developed by the EMCDDA in line with the Council conclusions of November 2013. The report gives also an...

Rapid communication

Medical use of cannabis and cannabinoids: questions and answers for policymaking

What is the evidence base for the medical use of cannabis and cannabinoids? What is the difference between cannabis preparations and medicinal products and why is this important? How is this issue regulated in the EU? These and other questions are explored in this report which responds to growing...

Publication cover

Technical reports

A summary of reviews of evidence on the efficacy and safety of medical use of cannabis and cannabinoids

This paper accompanies the report Medical use of cannabis and cannabinoids — questions and answers for policymaking and summarises the findings of major systematic reviews of the evidence on the effectiveness and safety of cannabis and cannabinoids when used to treat symptoms of various medical...

screenshot

Topic overviews

EU Early Warning System on NPS

This page describes the work and main outputs of the EU Early Warning System on new psychoactive substances. It includes a description of how the system work, an historical timeline of legislation and substances investigated, and NPS drug profiles.

publication cover

Joint publications

Exploring new and emerging drug trends and developments in CELAC countries: joint report from the EMCDDA and COPOLAD workshop on trendspotter methodology

This report details the results of a two-day workshop on the EMCDDA’s trendspotter methodology held in Lisbon in November 2017. The workshop involved representatives from national drug observatories based in countries from the Community of Latin American and Caribbean States (CELAC), along with...

Work programmes and strategies

EMCDDA International Cooperation Framework

This document is an update of the International Cooperation Strategy adopted in 2007. It sets priorities in the area of the international cooperation aligned with the Centre’s Strategy 2025.

Technical reports

Monitoring drug use in recreational settings across Europe: conceptual challenges and methodological innovations

This report explores how data on drug use are captured through surveys of targeted populations in recreational settings. The benefits and challenges of monitoring drug use in recreational settings are identified, as are emergent data sources and methodological innovations. The report draws on...

cover page emcdda budget 2018

Budget 2018

The EMCDDA receives stable funding under Commission budget line B3-441 of the general budget of the European Union. Each year, a preliminary draft budget is presented by the Centre's Director to the Management Board, which may modify the draft before adopting it and submitting it to the European...

Captagon: understanding today's illicit market

Captagon is reported to be a commonly used stimulant in the Middle East. In addition, some recent media reports have linked this drug to perpetrators of terrorist acts in Europe or terrorist groups based in areas of conflict in the Middle East. This report aims to provide an overview of what is...

Preventing overdose POD's cover

Perspectives on Drugs (PODs)

Preventing overdose deaths in Europe (Perspectives on drugs)

More than 9 000 lives were reported to be lost to drug overdoses in Europe (28 EU Member States, Turkey and Norway) in 2016, the latest reporting year, and this is an underestimate. Reducing drug-related deaths therefore remains a major challenge for public health policy. This analysis describes...

Risk assessments

Report on the risk assessment of 2-methoxy-N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]acetamide (methoxyacetylfentanyl) in the framework of the Council Decision on new psychoactive substances

This publication presents the data and findings of the risk assessment on 2-methoxy-N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]acetamide (methoxyacetylfentanyl), carried out by the extended Scientific Committee of the EMCDDA on 21 March 2018. On the basis of the Risk Assessment Report — and on the...

Risk assessments

Report on the risk assessment of N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]cyclopropanecarboxamide (cyclopropylfentanyl) in the framework of the Council Decision on new psychoactive substances

This publication presents the data and findings of the risk assessment on N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]cyclopropanecarboxamide (cyclopropylfentanyl), carried out by the extended Scientific Committee of the EMCDDA on 21 March 2018. On the basis of the Risk Assessment Report — and on...

European evidence-based guidance on prevention and control of HCV in prison settings (poster)

In the 31 EU/EEA countries, more than 590 000 persons are held in a custodial facility on any given day. According to recent reviews of prison studies from EU countries, prison prevalence estimates for HCV ranged from 4.3 % to 86.3 %. People in prison also tend to have multiple complex health and...

Topic overviews

Viral hepatitis policies in Europe (topic overview)

Hepatitis C virus (HCV) infection is the most common infectious disease in people who inject drugs, among whom it is usually transmitted through the sharing of syringes and other drug use equipment. Most of those who become infected go on to develop chronic HCV infection, which can lead to severe...

Barriers to HCV Testing in Drug Treatment Services for People who inject drugs

People who inject drugs (PWID) remain a key risk group for hepatitis C virus infection (HCV) with national prevalence estimates ranging from 13.8% (Malta) to 84.3% (Portugal) in Europe. To reach the global and European elimination goals, HCV testing and treatment of PWID is required at larger...

Poster on Supporting capacity-building, analysis and threat assessment in Europe’s neighbourhood

Poster: Supporting capacity-building, analysis and threat assessment in Europe’s neighbourhood

Partnership is a guiding principle for the EMCDDA as it works to increase its understanding of the external dimension of the drug phenomenon and its implications for public health and security in the EU and neighbouring countries. For more than a decade the EMCDDA has been working with countries...

1
2
3
4
next ›

.

Loading